Cell Prolif. 2024 Jul;57(7):e13681. doi: 10.1111/cpr.13681. Epub 2024 May 28.
L. Wang, B. Li, L. Zhang, Q. Li, Z. He, X. Zhang, X. Huang, Z. Xu, Y. Xia, Q. Zhang, Q. Li, J. Xu, G. Sun, Z. Xu, "miR-664a-3p functions as an oncogene by targeting Hippo pathway in the development of gastric cancer," Cell Proliferation 52, no. 3 (2019): e12567, https://doi.org/10.1111/cpr.12567. The above article, published online on 18 March 2019, in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor-in-Chief, Qi Zhou, and John Wiley and Sons Ltd. Following publication, concerns were raised by third parties regarding suspected duplication of figures 2c, 2d, 4g, 4h and 5a. The authors explained that the duplicates were a result of negligence during data storage. Due to the extent and nature of the mistakes made, the editors have lost confidence in the results and conclusions of this study.
王L、李B、张L、李Q、何Z、张X、黄X、徐Z、夏Y、张Q、李Q、徐J、孙G、徐Z,“miR - 664a - 3p在胃癌发生发展中通过靶向Hippo通路发挥癌基因作用”,《细胞增殖》52卷,第3期(2019年):e12567,https://doi.org/10.1111/cpr.12567 。上述文章于2019年3月18日在线发表于威利在线图书馆(wileyonlinelibrary.com),经期刊主编周琦与约翰·威利父子有限公司协商后已被撤回。文章发表后,第三方对图2c、2d、4g、4h和5a涉嫌重复提出了担忧。作者解释称这些重复是数据存储过程中的疏忽所致。鉴于所犯错误的程度和性质,编辑们对该研究的结果和结论失去了信心。